During the last session, Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT)’s traded shares were 0.37 million, with the beta value of the company hitting 2.62. At the end of the trading day, the stock’s price was $21.46, reflecting an intraday gain of 4.12% or $0.85. The 52-week high for the ARCT share is $45.00, that puts it down -109.69 from that peak though still a striking 18.36% gain since the share price plummeted to a 52-week low of $17.52. The company’s market capitalization is $580.28M, and the average intraday trading volume over the past 10 days was 0.36 million shares, and the average trade volume was 388.27K shares over the past three months.
Arcturus Therapeutics Holdings Inc (ARCT) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.09. ARCT has a Sell rating from 1 analyst(s) out of 6 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) trade information
Arcturus Therapeutics Holdings Inc (ARCT) registered a 4.12% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 4.12% in intraday trading to $21.46, hitting a weekly high. The stock’s 5-day price performance is -10.13%, and it has moved by 7.79% in 30 days. Based on these gigs, the overall price performance for the year is -11.14%. The short interest in Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) is 4.6 million shares and it means that shorts have 11.77 day(s) to cover.
The consensus price target of analysts on Wall Street is $66, which implies an increase of 67.48% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $14 and $140 respectively. As a result, ARCT is trading at a discount of -552.38% off the target high and 34.76% off the low.
Arcturus Therapeutics Holdings Inc (ARCT) estimates and forecasts
Statistics show that Arcturus Therapeutics Holdings Inc has underperformed its competitors in share price, compared to the industry in which it operates. Arcturus Therapeutics Holdings Inc (ARCT) shares have gone down -29.48% during the last six months, with a year-to-date growth rate less than the industry average at -30.65% against 17.50.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 12.40%. While earnings are projected to return -226.16% in 2024.
ARCT Dividends
Arcturus Therapeutics Holdings Inc is due to release its next quarterly earnings on 2024-Nov-12. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT)’s Major holders
Arcturus Therapeutics Holdings Inc insiders own 8.47% of total outstanding shares while institutional holders control 93.05%, with the float percentage being 101.66%. FEDERATED HERMES, INC. is the largest shareholder of the company, while 253.0 institutions own stock in it. As of 2024-06-30, the company held over 4.69 million shares (or 17.4067% of all shares), a total value of $114.3 million in shares.
The next largest institutional holding, with 2.65 million shares, is of BLACKROCK INC.’s that is approximately 9.8262% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $64.52 million.
